The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
|
|---|---|
| Published in |
Frontiers in oncology, July 2022
|
| DOI | 10.3389/fonc.2022.904800 |
| Pubmed ID | |
| Authors |
Luis E. Raez, Oscar Arrieta, Diego F. Chamorro, Pamela Denisse Soberanis-Piña, Luis Corrales, Claudio Martín, Mauricio Cuello, Suraj Samtani, Gonzalo Recondo, Luis Mas, Zyanya Lucia Zatarain-Barrón, Alejandro Ruíz-Patiño, Juan Esteban García-Robledo, Camila Ordoñez-Reyes, Elvira Jaller, Franco Dickson, Leonardo Rojas, Christian Rolfo, Rafael Rosell, Andrés F. Cardona |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 21% |
| Colombia | 4 | 17% |
| Greece | 1 | 4% |
| Switzerland | 1 | 4% |
| Italy | 1 | 4% |
| Mexico | 1 | 4% |
| Argentina | 1 | 4% |
| Unknown | 10 | 42% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 58% |
| Practitioners (doctors, other healthcare professionals) | 5 | 21% |
| Scientists | 5 | 21% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 2 | 14% |
| Researcher | 2 | 14% |
| Student > Bachelor | 2 | 14% |
| Other | 1 | 7% |
| Student > Master | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 5 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
| Economics, Econometrics and Finance | 1 | 7% |
| Sports and Recreations | 1 | 7% |
| Unknown | 7 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 June 2023.
All research outputs
#2,529,397
of 26,169,168 outputs
Outputs from Frontiers in oncology
#584
of 22,913 outputs
Outputs of similar age
#53,228
of 440,555 outputs
Outputs of similar age from Frontiers in oncology
#37
of 1,775 outputs
Altmetric has tracked 26,169,168 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,913 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,555 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 1,775 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.